ATXS241220C10000
- 0.35
- 0.000.00%
Astria Therapeutics Inc Newsroom
TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35
Astria Therapeutics (NASDAQ:ATXS) Is In A Good Position To Deliver On Growth Plans
A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $23 to $35
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Astria Therapeutics Is Maintained at Outperform by Oppenheimer
Astria Therapeutics Analyst Ratings
Express News | Astria Therapeutics : Oppenheimer Raises Target Price to $28 From $26
H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16
Astria TherapeuticS GAAP EPS of -$0.42 In-line
Astria Expects Cash, Cash Equivalents and Short-Term Investments as of Sept 30 Sufficient to Fund Ops Into Mid-2027 >ATXS
Astria Therapeutics: Final 3- and 6-Mo Results From ALPHA-STAR Trial of Navenibart Expected in 4Q
Astria Therapeutics: Phase 1a Trial of STAR-0310 in Healthy Subjects Expected to Initiate in Q1 2025 >ATXS
Astria Therapeutics 3Q Loss/Shr 42c >ATXS
Express News | Astria Therapeutics Inc - as of September 30, 2024, Astria Had Cash, Cash Equivalents and Short-Term Investments of $344.3 Mln
Press Release: Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Express News | Astria Therapeutics Q3 Income From Operations USD -29.014 Million
Express News | Astria Therapeutics Q3 Operating Expenses USD 29.014 Million
Express News | Astria Therapeutics Q3 Net Income USD -24.534 Million
Astria Therapeutics Inc | 10-Q: Q3 2024 Earnings Report
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25